JNeurol(2013)260:984–997
DOI10.1007/s00415-012-6739-4
ORIGINAL COMMUNICATION
A double-blind, randomized, placebo-controlled, parallel-group
study of THC/CBD oromucosal spray in combination
with the existing treatment regimen, in the relief of central
neuropathic pain in patients with multiple sclerosis
R. M. Langford • J. Mares • A. Novotna •
M. Vachova • I. Novakova • W. Notcutt •
S. Ratcliffe
Received:16August2012/Revised:17October2012/Accepted:29October2012/Publishedonline:21November2012
(cid:2)Springer-VerlagBerlinHeidelberg2012
Abstract Centralneuropathicpain(CNP)occursinmany placebo as an add-on treatment, in a double-blind manner,
multiplesclerosis(MS)patients.Theprovisionofadequate for14 weekstoinvestigatetheefficacyofthemedicationin
pain relief to these patients can very difficult. Here we MS-inducedneuropathicpain.Thisparallel-groupphaseof
report the first phase III placebo-controlled study of the the study was then followed by an 18-week randomized-
efficacyoftheendocannabinoidsystemmodulatordelta-9- withdrawal study (14-week open-label treatment period
tetrahydrocannabinol (THC)/cannabidiol (CBD) oromuco- plusadouble-blind4-week randomized-withdrawalphase)
sal spray (USAN name, nabiximols; Sativex, GW Phar- to investigate time to treatment failure and show mainte-
maceuticals, Salisbury,Wiltshire, UK), to alleviate CNP. nanceofefficacy.Atotalof339patientswererandomized
Patients who had failed to gain adequate analgesia from tophaseA(167receivedTHC/CBDsprayand172received
existing medication were treated with THC/CBD spray or placebo).OfthosewhocompletedphaseA,58entered the
randomized-withdrawal phase. The primary endpoint of
responderanalysisatthe30 %levelatweek14ofphaseA
Sativex,aTHC/CBDoromucosalspray,doesnothaveanINN.
of the study was not met, with 50 % of patients on THC/
NabiximolsistheUSAdoptedName(USAN).
CBD spray classed as responders at the 30 % level com-
R.M.Langford pared to 45 % of patients on placebo (p = 0.234). How-
PainandAnaesthesiaResearchCentre, ever, an interim analysis at week 10 showed a statistically
StBartholomew’sHospital,London,UK
significanttreatmentdifferenceinfavorofTHC/CBDspray
at this time point (p = 0.046). During the randomized-
J.Mares
Neurologicka´ KlinikaFakultni,NemocniceOlomoucI.P., withdrawalphase,theprimaryendpointoftimetotreatment
Olomouc,CzechRepublic failure was statistically significant in favor of THC/CBD
spray, with 57 % of patients receiving placebo failing
A.Novotna
treatmentversus24 %ofpatientsfromtheTHC/CBDspray
Neurologicke´ odd.,Krajska´ nemocnicePardubice,
Pardubice,CzechRepublic group (p = 0.04). The mean change from baseline in Pain
Numerical Rating Scale (NRS) (p = 0.028) and sleep
M.Vachova
quality NRS(p = 0.015) scores,both secondary endpoints
Neurologicke´ odd.,NefakultniRegionalniCentrum,
in phase B, were also statistically significant compared to
TepliceDuchcovska53,Teplice,CzechRepublic
placebo,withestimatedtreatmentdifferencesof-0.79and
I.Novakova 0.99 points, respectively, in favor of THC/CBD spray
MSCentrumKarlovonamesti,Prague2,CzechRepublic
treatment. The results of the current investigation were
equivocal,withconflictingfindingsinthetwophasesofthe
W.Notcutt
DepartmentofAnaesthesia,JamesPagetHospital,Norfolk,UK study.Whiletherewerealargeproportionofrespondersto
THC/CBDspraytreatmentduringthephaseAdouble-blind
S.Ratcliffe(&)
period,theprimaryendpointwasnotmetduetoasimilarly
MACClinicalResearch,CobraCourt,TraffordPark,
largenumberofplaceboresponders.Incontrast,therewasa
ManchesterM320UT,UK
e-mail:stuartratcliffe@macukneuroscience.com marked effect in phase B of the study, with an increased
123
JNeurol(2013)260:984–997 985
time to treatment failure in the THC/CBD spray group analgesic properties that were effective in relieving neu-
compared to placebo. These findings suggest that further ropathic pain. These studies also suggested that the medi-
studies are required to explore the full potential of THC/ cationwaswelltoleratedandcouldalsoimprovesleepand
CBD spray inthesepatients. quality of life. A 2-year, open-label follow-up study
showedcontinuedeffectivenesswithTHC/CBDspray,and
Keywords Cannabidiol (cid:2) Cannabinoid (cid:2) no evidence of tolerance was seen in the 28 patients who
Central neuropathic pain (cid:2) Delta-9-tetrahydrocannabinol (cid:2) completed the study [21]. Furthermore, a meta-analysis of
Multiple sclerosis (cid:2) THC/CBD oromucosal spray THC/CBD spray, dronabinol (synthetic THC) and CBD in
neuropathic and MS-related pain revealed statistically
significant pain relief in these studies [22].
Introduction This study assessed the efficacy of THC/CBD spray on
CNP due to MS, as well as evaluating the effect of the
Multiple sclerosis (MS) is a progressive inflammatory medication on sleep quality, quality of life, and patients
disease of the central nervous system (CNS) caused by perception of CNP after 14 weeks of treatment (phase A,
axonal demyelination. Thought to be autoimmune in ori- double-blind). Phase B of the study (randomized-with-
gin,MSresultsindysfunctionoftheCNS,causingarange drawal)investigatedthemaintenanceofefficacyafterlong-
of symptoms including spasticity, spasms, fatigue, bladder term treatment with THC/CBD spray in the indication of
dysfunction and pain. With an estimated prevalence of CNP in MS, and assessed the absence or occurrence of
50–120 per 100,000, it is the most common cause of withdrawal symptoms.
neurological disability among young adults in the United
Kingdom (UK) [1, 2].
Central neuropathic pain (CNP) caused by a lesion or Methods
dysfunction of the CNS is a common symptom of MS,
affecting between 17 and 52 % of MS patients [3–9]. This The study was conducted in two phases and took place in
type of pain can be difficult to treat, with current treatment 33 study sites (UK, 12; Czech Republic, seven; Canada,
regimensincludingtricyclicantidepressants,gabapentinoids, five; Spain, five and France, four). It was approved by the
andcarbamazepine[10–12],causingsideeffectsthatmaybe relevant independent review board/ethics committee in
problematic.Aclassofcompoundscalledcannabinoidshave each of the countries, and was conducted in accordance
beenshowntohavetherapeuticeffectsinanimalmodelsof with good clinical practice guidelines.
CNP via interactions with specific cannabinoid receptors Phase A was a double-blind, randomized, placebo-con-
(CBRs) [13]. Endogenously released cannabinoids, such as trolled,14-weektreatmentphasetoevaluatetheefficacyof
anandamideand2-arachidonoylglycerol,actviatheseCBRs, THC/CBDsprayinthetreatmentofCNPinMSpatientsin
designatedCB andCB [14].CB receptorsarefoundpre- additiontoexistingtreatmentregimens.A1-weekbaseline
1 2 1
dominantlyatnerveterminalswheretheymediateinhibition period allowing for dosing optimization preceded the
of neurotransmitter release. CB receptors are expressed 14-week treatment phase. Response was assessed using a
2
mainlybyimmunecells,thefunctionsofwhichincludethe validated self-reported 0–10 point numerical rating scale
modulationofcytokinereleaseandofimmunecellmigration (NRS), where mean daily CNP due to MS was scored.
bothwithinandoutsidetheCNS[15].CB andCB receptors Phase B was a 14-week open-plan treatment phase con-
1 2
aretargetedbyagonistsproducedinmammaliantissues,and sisting of a 2-week re-titration period and 12-week stable
this system of receptors and endocannabinoids together dose phase with THC/CBD spray, with an additional
constitute the endocannabinoid system. Cannabinoids may 4-week randomized-withdrawal phase, where patients
also demonstrate activity at other receptors including the received either THC/CBD spray or placebo in a double-
orphan G protein-coupled receptor 55, transient receptor blind manner. The maintenance of efficacy with long-term
potentialvannilloid-1andadenosinereceptors[16–18]. treatment with THC/CBD spray was investigated, and the
Delta-9-tetrahydrocannabinol(THC)/cannabidiol(CBD) frequency and severity of withdrawal symptoms assessed.
sprayisderived fromextracts oftheplantCannabissativa
L., and is an endocannabinoid system modulator. It con- Randomization
tains THC and CBD in an approximate 1:1 ratio, and was
recentlyapprovedforuseinseveralEuropeancountriesfor Randomizationoccurredusingapre-determinedcomputer-
treating spasticity in MS patients [19]. generated randomization code in which treatment alloca-
A recent study in central MS pain using THC/CBD tion was stratified by center, and used randomly permuted
sprayshowed abeneficialeffect overplacebo[20].During blocks of variable sizes. Separate randomization schemes,
phaseIIandIIIstudies,THC/CBDspraywasfoundtohave usingthesamestrategy,wereproducedforeachpartofthe
123
986 JNeurol(2013)260:984–997
study. Patients, investigators, and those assessing the data re-titration period, patients were instructed to administer
werethereforeblindedtothepatients’treatmentallocation. one spray on days 1 and 2, two sprays on days 3 and 4,
three sprays on day 5, four on day 6, five on day 7 and so
Main inclusion and exclusion criteria on until reaching the maximum dose of 12 daily sprays on
day 14. Re-titration took place as it was assumed that a
Main study entry inclusion criteria numberofpatientswhoreceivedplaceboinphaseAwould
embark on active treatment in phase B. Since phase A of
Eligible subjects were to have CNP due to MS, of at least the study was still blinded, all patients underwent re-titra-
3 monthsduration.Subjectswerealsotohaveasumscore tion in phase B.
of at least 24 on a pain 0–10 point NRS on the last 6 days
during the baseline period. In addition, their analgesic Study endpoints
regimenwastobestableforatleast2 weeksprecedingthe
study entry day. Efficacy endpoints
Phase B (randomized-withdrawal) TheprimaryefficacyendpointforphaseAwastheresponse
totreatment,definedasanimprovementof30 %ormorein
French and Czech patients who had completed phase A of patient’s mean pain NRS score from baseline to the last
thestudywereinvitedtotakepartinphaseB.Patientswere week of treatment in phase A. In phase B, it was time to
required to have received an average of three or more treatmentfailureduringtherandomized-withdrawalperiod.
sprays of THC/CBD per day in the 7 days prior to com- Secondary efficacy endpoints for both phases included
pletion of phase A, shown tolerability to the study medi- the Brief Pain Inventory—Short Form, Subject Global
cation, and maintained a stable treatment regimen Impression of Change, and sleep quality assessments.
throughout the study for all neuropathic pain medications.
Safety endpoints
Main exclusion criteria
In both phases, the incidences of AEs were assessed.
Patients with severe pain from other concomitant condi-
tions were excluded. This included pain of a nociceptive, Statistical methods
musculoskeletal(includingspasms),peripheralneuropathic
or psychogenic origin, or due to trigeminal neuralgia. Sample size
Patientswerealsoexcludediftheyhadotherpainthatwas
not of a central neuropathic origin thought by the investi- A previous 4-week GW study in patients with CNP due to
gator to be of a nature or severity to interfere with the MSresultedin37.5and51.5 %ofplaceboandTHC/CBD
patient’s assessment of neuropathic pain due to MS. spray patients, respectively, achieving a 30 % reduction
Patientswithahistoryofsignificantpsychiatric(otherthan (improvement) in mean pain NRS scores; representing an
depression associated with their underlying condition), odds ratio of 1.71 for responding with THC/CBD spray
renal, hepatic, cardiovascular, or convulsive disorders, or compared with placebo. Given the longer duration of this
with a sensitivity to cannabis or cannabinoids, were also study,itwasassumedthattheoddsratioachievedwouldbe
excluded. Participants who had experienced an adverse 1.90, leading to an anticipated responder rate of 53.3 %
event (AE) in phase A were also excluded from phase B. withTHC/CBDspray,assumingtheplaceboresponderrate
did not change. Therefore, to obtain a 30 % response with
Treatment groups and doses THC/CBD spray compared with placebo, a total of 312
patients (156 in each group) were required in order to
A pump-action oromucosal spray delivered the study detect, with 80 % power at the a = 0.05 level, a statisti-
medication. Each 100-ll actuation of active medication callysignificantdifferencebetweenthetreatmentgroups.It
delivered 2.7 mg of THC and 2.5 mg of CBD to the oral was estimated that between 60 and 80 patients would be
mucosa. Placebo delivered the excipient plus colorants. eligible to enroll in phase B of the study. However, there
Patients were restricted to a maximum of 12 sprays per was no formal intended sample size for phase B.
24-h period. During the baseline period, patients self-
titrated, titrating upwards via a pre-defined escalation Phase A
scheme to reach their optimal dose depending on efficacy,
tolerability, and maximum permitted dose. To escalate the The baseline CNP NRS value was the average of the
dose to a maximum of 12 daily sprays during the phase B 7 days scores in baseline week one, with the variable for
123
JNeurol(2013)260:984–997 987
analysisbeingthechangeinpainNRSscoresfrombaseline displayed in Table 1A, B. The demographics between the
to end of treatment (average of final 7 days scores). The twostudygroupsweresimilarwithameandurationofMS
primary analysis was performed on the intention-to-treat in excess of 11 years, and neuropathic pain in excess of
(ITT)populationandatwo-sidedsignificancetestwasused 5 years. During phase A, patients receiving placebo
in all comparisons at the 5 % level of significance and a administered an average of 11.1 (SD = 4.6) daily sprays
95 % confidence interval (CI) was presented for the dif- compared to 8.8 (SD = 3.87) sprays in the THC/CBD
ference between baseline and endpoint. group. In the open-label stage ofphase B, patients took an
average of 6.7 (SD = 2.48) daily sprays. During random-
Phase B ized-withdrawal the active treatment group administered
on average 7.3 (SD = 2.42) sprays daily compared with
Time to treatment failure was analyzed using Kaplan– 8 (SD = 2.72) daily sprays by the placebo group
Meiersurvivalanalysismethodologyandproportionalodds (Table 1A, B).
modeling, with randomized treatment as a factor. Second-
aryefficacyvariables forbothstudieswere analyzed using Concomitant medication
analysis of covariance (ANCOVA).
Paracetamol was provided for rescue analgesic use during
both study phases. The majority of patients in both phases
Results were receiving this and other concomitant analgesic med-
ications (details presented in Table 2). As would be
A summary of breakdown of patients enrolled in phases expected in this group of patients, most were taking med-
A and B of the study are shown in Fig. 1a, b, respec- icationotherthananalgesicsduringthecourseofthestudy
tively, and respective study population demographics are (92 % phase A; 93 % phase B).
Fig.1 Dispositionofpatients
a
inphaseA(A)andphaseB(B). Screened
(n= 393)
*OneSubjectcompletedthe
open-labelpartofPhaseBbutat
thestartoftherandomized-
withdrawalphasenolonger Screen failures (n= 54)
wantedtocontinueinthestudy Did not meet entry criteria: 44
Adverse event: 1
astheyhadexperiencedAEs
Withdrew consent: 6
Other: 3
Phase A
Randomized
(n= 339)
THC/CBD
Placebo
spray
(n= 172)
(n= 167)
Withdrawal (n= 26) Withdrawal (n= 16)
Adverse event: 14 Adverse event: 9
Withdrew consent: 3 98 Days of treatment Withdrew consent: 2
Lack of efficacy: 3 Lack of efficacy: 4
Other: 6 Other: 1
Completed Completed
(n= 141) (n= 156)
ITT Set (n= 339)
PP Set (n= 326)
Safety Set (n= 339)
123
988 JNeurol(2013)260:984–997
Fig.1 continued
b Entered open-label
THC/CBD spray
treatment
(n= 58)
Withdrawal (n= 5)
12 Weeks of treatment Adverse event: 3
Withdrew consent: 1
Lack of efficacy: 1
Completed
(n= 53)*
Screened
Randomized-
withdrawal phase
(n= 52)
Withdrawal (n= 10)
Withdrew consent: 4
Lack of efficacy : 4
Adverse event: 1
Did not meet entry criteria: 1
Entered randomized-
withdrawal phase
(n= 42)
THC/CBD
Placebo
spray
(n= 21)
(n= 21)
Withdrawal (n= 1)
28 Days of treatment Adverse event: 1
Completed Completed
(n= 21) (n= 20)
Analysis Set (n= 42)
Safety Set (n= 42)
Primary analysis: responder analysis compared to -1.76 points (from a baseline score of
6.61 ± 1.29–4.73 ± 2.26) for the placebo group, an esti-
Phase A matedtreatmentdifferenceof0.17pointsinfavorofTHC/
CBD spray, which did not reach statistical significance
Thenumberofrespondersatthe30 %improvementlevelin (95 %CI: -0.62 to0.29 points; p = 0.47) (Fig. 3).
mean pain NRS score inthe last week oftreatment totaled
50 % in the THC/CBD spray group compared to 45 % in Phase B
the placebo group (odds ratio 1.31 [95 % CI: 0.84–2.04
points]:p = 0.234)(Fig. 2).Atweek10ofthestudy,there A marked increase in the time to treatment failure was
wasasignificanttreatmentdifferenceinfavorofTHC/CBD observed in the active treatment group in phase B, with
spray (odds ratio 1.61 [95 % CI: 1.01–2.57]: p = 0.046) only 24 % of patients failing treatment with THC/CBD
(Fig. 2).Attheendoftreatment,themeanreductioninpain spray compared to 57 % from the placebo group, which
0–10NRSscoreforTHC/CBDspraytreatmentwas-1.93 reached statistical significance (logrank test for equality of
points(fromabaselinescoreof6.55 ± 1.35–4.54 ± 2.24) curvesp = 0.04)(Fig. 4).Thehazardratio(0.374)fortime
123
JNeurol(2013)260:984–997 989
Table1 DemographicsandbaselinecharacteristicsforallpatientswhocompletedphaseAofthestudy(A)andphaseBofthestudy(B)
No.ofpatients(%)
THC/CBDspray Placebo Total
(n=167) (n=172) (n=339)
A
Gender
Male 54(32) 55(32) 109(32)
Female 113(68) 117(68) 230(68)
Ethnicorigin
White/Caucasian 165(99) 167(97) 332(98)
Black/AfricanAmerican 2(1) 2(1) 4(1)
Asian 0(0) 2(1) 2(1)
Other 0(0) 1(1) 1(\0.5)
Previouscannabisuseinthelastyear 11(7) 10(6) 21(6)
Mean(SD)
Age(years) 48.42(10.43) 49.51(10.50) 48.97(10.47)
BMI(kg/m2) 26.64(5.27) 26.02(4.97) 26.33(5.12)
DurationofMS(years) 11.42(8.00) 12.53(8.50) 11.99(8.26)
DurationofCNP(years) 5.59(6.12) 5.33(4.80) 5.46(5.49)
BaselinepainNRS 6.55(1.35) 6.61(1.29) 6.58(1.32)
SubtypeofMS
Primaryprogressive 18(11) 22(13) 40(12)
Secondaryprogressive 65(39) 71(41) 136(40)
Relapsing/remitting 80(48) 77(45) 157(46)
Progressiverelapsing 4(2) 2(1) 6(2)
Disease-modifyingtreatmentstakenduringphaseA
Totalnumberofpatients 100(60) 100(58) 200(59)
Glucocorticoids 59(35) 73(42) 132(39)
Interferons 44(26) 39(23) 83(24)
Otherimmunosuppressiveagents 29(17) 28(16) 57(17)
Selectiveimmunosuppressiveagents 17(10) 15(9) 32(9)
Nitrogenmustardanalogues 6(4) 13(8) 19(6)
Folicacidanalogues 7(4) 5(3) 12(4)
No.ofsubjects(%)
Open-label Randomized-withdrawal
THC/CBDspray THC/CBDspray Placebo Total
(n=58) (n=21) (n=21) (n=42)
B
Gender
Male 21(36) 10(48) 7(33) 17(40)
Female 37(64) 11(52) 14(67) 25(60)
Ethnicorigin
White/Caucasian 57(98) 21(100) 21(100) 42(100)
Previouscannabisuseinthelastyear 2(3) 0 1(5) 1(2)
Mean(SD)
Age(years) 48.00(9.41) 46.20(10.39) 49.82(9.75) 48.01(10.12)
BMI(kg/m2) 25.32(5.77) 24.88(5.07) 26.66(4.88) 25.77(5.00)
DurationofMS(years) 11.96(8.19) 12.56(8.03) 10.43(8.60) 11.50(8.29)
DurationofCNP(years) 6.18(6.98) 5.76(5.87) 5.72(8.97) 5.74(7.48)
123
990 JNeurol(2013)260:984–997
Table1 continued
No.ofsubjects(%)
Open-label Randomized-withdrawal
THC/CBDspray THC/CBDspray Placebo Total
(n=58) (n=21) (n=21) (n=42)
BaselinepainNRS 6.60(1.35) 6.21(1.37) 6.49(1.31) 6.35(1.33)
SubtypeofMS
Primaryprogressive 4(7) 3(14) 0 3(7)
Secondaryprogressive 22(38) 4(19) 9(43) 13(31)
Relapsing/remitting 29(50) 14(67) 11(52) 25(60)
Progressiverelapsing 3(5) 0 1(5) 1(2)
Disease-modifyingtreatmentstakenduringphase
Totalnumberofpatients 48(83) 17(81) 18(86) 35(83)
Folicacidanalogues 1(2) – – –
Glucocorticoids 34(59) 15(71) 10(48) 25(60)
Interferons 10(17) 3(14) 6(29) 9(21)
Nitrogenmustardanalogues 6(10) 1(5) 2(10) 3(7)
Otherimmunosuppressiveagents 11(19) 3(14) 5(24) 8(19)
Selectiveimmunosuppressiveagents 11(19) 4(19) 4(19) 8(19)
to treatment failure was also in favor of THC/CBD spray, Phase B
with the 90 % CI excluding unity, suggesting a real dif-
ference between treatments (90 % CI: 0.155–0.902; DuringphaseB,thechangeinmeanpainNRSscoreatthe
p = 0.054) (Fig. 4). endofthetreatmentgaveanestimatedtreatmentdifference
of-0.79pointsinfavorofTHC/CBDspray,astatistically
Secondary endpoints significant difference in pain (90 % CI: -1.37 to -0.21
points; p = 0.028) (Table 3B).
Phase A During randomized-withdrawal, a significant difference
inthesleepqualityNRSscoreinfavorofTHC/CBDspray
None of the secondary efficacy endpoints demonstrated a was observed, the results of which are summarized in
statistically significantly treatment difference in favor of Table 3B. All other secondary endpoints from phase B
THC/CBD spray (Table 3A). showedatreatmentdifferenceinfavorofTHC/CBDspray,
Table2 SummaryofallconcomitantanalgesicmedicationsbeingusedbyrandomizedpatientsinphasesAandBofthestudy
Medicationclass/name No.ofpatients(%)
PhaseA PhaseB
Open-label Randomized-withdrawal
THC/CBDspray Placebo THC/CBDspray THC/CBDspray Placebo
(n=167) (n=172) (n=58) (n=21) (n=21)
Anticonvulsant 76(46) 96(56) 26(45) 7(33) 13(62)
NSAID 58(35) 57(33) 20(34) 8(38) 7(33)
Otheranalgesics 91(54) 104(60) 45(78) 17(81) 14(67)
Tricyclicanti-depressants 75(45) 73(42) 21(36) 6(29) 9(43)
Otheropioid 33(20) 31(18) 10(17) 4(19) 4(19)
Strongopioids 7(4) 7(4) 2(3) 0 1(5)
Antiarrhythmic 0 1(1) 0 0 0
Atleastoneanalgesic 153(92) 167(97) 58(100) 21(100) 21(100)
123
but only two reached statistical significance (see medicationduetoAEs.Ofthese,eightpatients(2 %)(five
Table 3B). [3 %]intheTHC/CBDspraygroupandthree[1 %]inthe
placebogroup),permanentlystoppedstudymedicationdue
Safety and tolerability tosevereAEsand18(5 %)(12intheTHC/CBDsprayarm
andsixintheplaceboarm)wereconsideredtobetreatment-
All AEs experienced by patients in phase A and B are related.ThemajorityofAEsleadingtopermanentcessation
displayed in Table 4A, B, respectively. During phase A, a of study medication were within the nervous system dis-
totalof27patients(8 %),15(9 %)intheTHC/CBDspray orders and gastrointestinal disorders system organ classes
group and 12 (7 %) in the placebo group, stopped study (SOCs).There was nosignificant difference in the number
of patients that ceased study medication between the two
arms of the study but there were twice the number of
60
treatment-related AEs amongst patients ceasing study
medication from the THC/CBD spray group than from the
50
placebo group (Table 4A). Thirty-five patients (10 %) in
phase A experienced a severe treatment-emergent AE, 21
40
(13 %) in the THC/CBD spray group and 14 (8 %) in the
30 placebo group. AEs with severe intensity were observed
mostofteninthenervoussystemdisorders,gastrointestinal
20 system disorders, and psychiatric system disorders SOCs.
Overall, the difference in the incidence of severe events
10
betweenthetwotreatmentarmswassmallandinsignificant.
In the nervous system disorders SOC, there were twice as
0
2 6 10 14 many patients with severe events in the THC/CBD spray
Study period (weeks) group than in the placebo. In the psychiatric SOC, there
wereequalproportionsofpatientswithsevereeventsinthe
active and placebo study medication arms. No patient
experienced a severe event on more than two occasions.
ni
enilesab
morf
tnemevorpmi
egatnecreP
SRN
01-0
niap
*P= 0.046 *
THC/CBD spray
Placebo
Fig.2 Percentageofpatientsgaininga30%responseimprovement
frombaselineinpain0–10NRS(intention-to-treatanalysis)inphase
Aofthestudy
8
6
4
Study period (week)
)ES(
SRN
01-0
niap
naeM
Fig.3 Meanpain0–10NRS
scoresduringthetreatment
periodofphaseA(intention-to- 7 THC/CBD spray
treatanalysis) Placebo
5
3
Placebo
Log rank test: P= 0.040
THC/CBD spray Hazard ratio: 0.374
eruliaf
tnemtaert
fo
ytilibaborP
JNeurol(2013)260:984–997 991
Fig.4 Probabilityoftreatment 1.0
failureinpatientsreceiving 0.9
THC/CBDsprayorplacebo
0.8 duringrandomized-withdrawal
0.7
inphaseBofthestudy
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 7 14 21 28
Treatment time (days)
123
992 JNeurol(2013)260:984–997
Table3 SummaryofprimaryandsecondaryefficacyresultscomparingmeanvaluesofTHC/CBDsprayvs.placebo,frombaselinetoendof
treatmentduringphaseAofthestudy(A)andphaseBofthestudy(B)
Variable Summaryofprimaryandsecondaryefficacyendpoints:PhaseA
THC/CBDspray Placebo Treatment pvalue
(mean) (mean) difference
A
30%responder 0.5 0.45 0.06 0.234
50%responder 0.3 0.28 0.02 0.714
NPS -12.41 -10.58 1.83 0.310
SleepqualityNRS -1.96 -2.00 0.05 0.833
BPI-SF -1.47 -1.35 -0.12 0.564
Breakthroughanalgesia -1.15 -0.91 -0.24 0.157
PDI -3.25 -6.04 2.79 0.058
SpasticityNRS -1.19 -1.09 -0.1 0.667
BladderNRS -0.56 -0.78 0.22 0.364
SpasmseverityNRS -1.06 -0.92 -0.14 0.548
TremorNRS -0.51 -0.77 0.25 0.216
FatigueNRS -0.96 -1.28 0.32 0.176
EQ-5DHealthstateindex 0.05 0.07 -0.01 0.396
EQ-5DHealthstatusVAS 7.20 5.26 1.94 0.383
SF-36
Physicalfunctioning 1.56 2.02 -0.45 0.785
Rolephysical 5.62 6.51 -0.89 0.694
Bodilypain 11.36 10.01 1.35 0.494
Generalhealth 2.32 4.02 -1.70 0.264
Vitality 3.72 6.47 -2.75 0.095
Socialfunctioning 3.62 9.37 -5.75 0.020
Roleemotion -0.18 3.15 -3.33 0.216
Mentalhealth 3.17 3.73 -0.56 0.733
95%confidenceinterval
Lower Upper Oddsratio
SGIC 0.99 2.18 1.47 0.055
Procedure Summaryofprimaryandsecondaryefficacyendpoints:randomized-withdrawal(PhaseB)
Primaryefficacymeasure:timetotreatmentfailure
Test Chi-square df pvalue
B
Kaplan–Meier Logrank 4.22 1 0.040
Proportionalhazardregression(1) Likelihoodratio 4.01 1 0.045
Proportionalhazardregression(2) Likelihoodratio 3.72 1 0.054
Variable Secondaryefficacyendpointsduringrandomized-withdrawal
THC/CBDspray Placebo Treatmentdifference pvalue
(mean) (mean)
IVRSpainNRS -0.03 0.76 -0.79 0.028
NPS -0.93 5.87 -6.8 0.153
SleepqualityNRS -0.07 0.92 -0.99 0.015
SpasticityNRS -0.12 0.63 -0.75 0.150
BladdersymptomsNRS -0.10 0.60 -0.70 0.114
123
JNeurol(2013)260:984–997 993
Table3 continued
Variable Secondaryefficacyendpointsduringrandomized-withdrawal
THC/CBDspray Placebo Treatmentdifference pvalue
(mean) (mean)
SpasmseverityNRS -0.07 0.97 -1.05 0.095
TremorNRS 0.00 0.20 -0.19 0.766
FatigueNRS -0.35 0.21 -0.56 0.439
95%confidenceinterval
Lower Upper Oddsratio
SGIC 0.486 3.245 1.25 0.69
During the post-randomization part of phase B, the AE leasta30 %improvementfrombaselineinmeanpainNRS
profile was similar between groups (Table 4B). The most score was significantly greater than on placebo, reflecting
commonAEsintheTHC/CBDspraygroupweredizziness, the fact that new placebo responses occurred in the final
fatigue, somnolence, vertigo, and nausea. There were weeks of treatment, while the effect with THC/CBD spray
reports of three serious adverse events (SAE) during the remained steady. Consistent with two previously reported
courseofthisstudy.Onepatient(5 %)receivingTHC/CBD GW studies, the placebo response appears to be related to
spray experienced serious disorientation, and two patients, dosing design, whereby patients were able to self-admin-
one (5 %) receiving THC/CBD spray and the other (5 %) istertheoralsprayatwill,uptoamaximumpermitteddaily
receivingplaceboexperiencedtheSAEofsuicidalideation. dose. This was originally intended to reflect as far as pos-
Six patients (10 %) stopped their study medication perma- sible the ‘‘real-world’’ use of THC/CBD spray, whereby
nently because of AEs in the open-label part of phase B. patients initially experiment with dosing to find their opti-
During this phase, four patients (11 %) had treatment- mum dose level and which, once established, is usually
relatedeventsandallhadpreviouslybeenreceivingplacebo maintained thereafter. However, the consequence of
prior to entering phase B of the study. In the randomized- allowingpatientstodeterminetheirowndosewasthatthose
withdrawalphaseofthestudy,onlyonepatientonplacebo onplacebotook significantlymoredosesthanthoseonthe
ceasedtoparticipateinthestudypermanentlyasaresultof THC/CBD spray, potentially confounding the comparison
asevereSAEofaccidentalinjury.TheSAEwasconsidered between treatment groups. Placebo group patients who
unrelatedtothe placebo medication. titrated to the maximum dose had disproportionate
improvementsinpainscores,andanumberofthesepatients
reached the maximum permitted dose as the study period
Discussion was drawing to a close. Self-titration combined with a
subjective endpoint seems therefore to have significantly
The results of phase A of this study failed to show a sig- impacted the placebo response. Other recent studies also
nificant difference between THC/CBD spray and placebo report high placebo response rates, and rates appear to be
in the primary and in the majority of secondary efficacy growing inclinical research ingeneral [25, 26].
endpoints. However, the results from a phase A interme- In an attempt to identify any subgroup of patients who
diate time point analyses and phase B of the study dem- may have been responsible for this finding in phase A of
onstrate evidence of the efficacy of THC/CBD spray with the study, we carried out a number of unplanned, post hoc
both the primary and certain secondary endpoints showing analyses. As might be predicted from the observation that
asignificantdifferenceinfavorofTHC/CBDspray.These patients on placebo took a greater number of daily sprays,
apparently paradoxical results make the interpretation of when the groups were balanced for daily sprays, the THC/
this study difficult. CBD spray group showed greater separation from placebo
The overall response of patients in phase A was good, (data not shown). There was no notable difference in the
bothtoactiveandplacebomedication.Inpublishedstudies response rates according to gender, MS subtype, or indi-
of THC/CBD spray in neuropathic pain to date, this is the vidual neuropathic pain type, but patients with a short
largest placebo effect described by a substantial margin history of neuropathic pain (less than 4 years) appeared to
[20–24]. At week 10 of this 14-week study, the proportion respondbetterthanthosewithalonghistoryofpain.These
of patients in the THC/CBD spray group who achieved at analyses,beingposthocandunplanned,cannotchangethe
123
994 JNeurol(2013)260:984–997
Table4 Treatment-relatedadverseeventsoccurringinatleast3%ofthestudypopulationduringphaseA(A)andphaseB(B)
Systemorganclass THC/CBDspray Placebo
Preferredterm (n=167) (n=172)
n(%) n(%)
A
TotalpatientswithatleastoneAE 120(75) 106(62)
Earandlabyrinthdisorder 20(12) 9(5)
Vertigo 15(9) 6(3)
Eyedisorder 7(4) 5(3)
Visionblurred 4(2) 1(1)
Gastrointestinaldisorder 54(32) 40(23)
Nausea 13(8) 7(4)
Drymouth 12(7) 10(6)
Diarrhea 7(4) 5(3)
Vomiting 5(3) 5(3)
Generaldisordersandadministrationsiteconditions 40(24) 30(17)
Fatigue 16(10) 9(5)
Feelingabnormal 5(3) 2(1)
Pain 0 1(1)
Infectionsandinfestations 34(20) 27(16)
Musculoskeletalandconnectivetissuedisorders 17(10) 20(12)
Paininextremity 0 1(1)
Muscularweakness 1(1) 1(1)
Nervoussystemdisorders 73(44) 51(30)
Dizziness 34(20) 7(4)
Somnolence 16(10) 3(2)
Headache 7(4) 6(3)
Disturbanceinattention 6(4) 1(1)
Dysgeusia 6(4) 1(1)
Memoryimpairment 6(4) 1(1)
Balancedisorder 5(3) 2(1)
Psychomotorskillsimpaired 5(3) 0
Neuralgia 1(1) 1(1)
Psychiatricdisorders 27(16) 12(7)
Depression 2(1) 0
Respiratory,thoracic,andmediastinaldisorders 8(5) 11(6)
Pharyngolaryngealpain 2(1) 1(1)
Systemorganclass Open-label Randomized-withdrawal
Preferredterm
THC/CBDspray Placebo THC/CBDspray Placebo
(n=21) (n=37) (n=21) (n=21)
n(%) n(%) n(%) n(%)
B
TotalpatientswithatleastoneAE 8(38) 18(49) 2(10) 5(24)
Cardiacdisorders 0 1(3) 0 0
Earandlabyrinthdisorders 1(5) 7(19) 0 0
Vertigo 1(5) 7(19) 0 0
Gastrointestinaldisorders 1(5) 3(8) 0 0
Paraesthesiaoral 1(5) 0 0 0
Diarrhea 0 1(3) 0 0
Drymouth 0 1(3) 0 0
123
JNeurol(2013)260:984–997 995
Table4 continued
Systemorganclass Open-label Randomized-withdrawal
Preferredterm
THC/CBDspray Placebo THC/CBDspray Placebo
(n=21) (n=37) (n=21) (n=21)
n(%) n(%) n(%) n(%)
Hypoaesthesiaoral 0 1(3) 0 0
Nausea 0 1(3) 0 0
Vomiting 0 1(3) 0 0
Generaldisordersandadministrationsiteconditions 1(5) 4(11) 1(5) 0
Fatigue 1(5) 2(5) 0 0
Feelingdrunk 0 1(3) 0 0
Mucosalerosion 0 0 1(5) 0
Hepatobiliarydisorders 0 1(3) 0 0
Infectionsandinfestations 1(5) 3(8) 0 0
Investigations 0 0 0 1(5)
Hepaticenzymeincreased 0 0 0 1(5)
Musculoskeletalandconnectivetissuedisorders 0 2(5) 0 1(5)
Paininextremity 0 1(3) 0 0
Nervoussystemdisorders 2(10) 8(22) 0 2(10)
Ageusia 0 1(3) 0 0
Cognitivedisorder 0 1(3) 0 0
Dysarthria 0 1(3) 0 0
Headache 0 1(3) 0 0
Hypersomnia 1(5) 0 0 0
Monoparesis 0 1(3) 0 0
Quadriparesis 0 1(3) 0 0
Somnolence 0 2(5) 0 0
Tremor 0 1(3) 0 0
Psychiatricdisorders 2(10) 1(3) 1(5) 1(5)
Depression 0 0 1(5) 0
Insomnia 1(5) 0 0 1(5)
Reproductivesystemandbreastdisorders 1(5) 0 0 0
Skinandsubcutaneoustissuedisorders 1(5) 0 0 1(5)
Dryskin 0 0 0 1(5)
MSmultiplesclerosis.BolditemsindicatethetotalnumbersofpatientswithanAEbySystemOrganClass(SOC)accordingtotheMedDRA
classificationofAEs
conclusion that phase A of this study failed to show a study medication in relation to the active treatment, which
significant difference between THC/CBD spray and pla- is something to consider in the design of future studies.
cebo, but they may help to inform the design of future The primary efficacy endpoint of time to treatment
studies.Thesubgroupanalysessuggestthatpatientswitha failure in phase B was in favor of the THC/CBD spray,
long history of refractory pain may be less likely to with significantly more patients from the placebo group
respond—a conclusion that may seem intuitive, but is failingtreatmentcomparedwithpatientsrandomizedtothe
supportedbytheposthocanalysesofphaseAofthisstudy. THC/CBD spray. Moreover, the results of all other
In contrast to phase A, patients in phase B were symptom-related endpoints showed that THC/CBD spray
instructed to remain on a stable daily dose of study medi- patients maintained or improved their response whilst the
cation. In this case, THC/CBD spray demonstrated an symptomsofthosewhoswitchedfromTHC/CBDsprayto
analgesic effect, with time to withdrawal being signifi- placebo worsened in the 4 weeks following cessation of
cantly longer in the THC/CBD spray treatment group. active treatment.
Thus, it is important to ensure that patients in placebo- The European Medicines Agency guidelines acknowl-
controlledstudiestakeabalancednumberofdailydosesof edgethatpatientswithseverepain,especiallyifpreviously
123
996 JNeurol(2013)260:984–997
treated,maynotrespondtonewtherapies.Consideringthat maintenance of effect with THC/CBD spray was demon-
the average duration of pain in this study was in excess of strated both for the primary outcome measure of time to
5 years, and many patients had failed to respond ade- treatment failure, and for the key pain-related secondary
quately to previous medications, the patients investigated measuresofsleepandmeanpainscores.Weconcludethat
here represented an especially resistant treatment group this study has provided further results useful for deter-
[27]. The fact that more than half of the patients who miningtheefficacy ofTHC/CBD sprayinthetreatmentof
receivedTHC/CBDsprayinphaseAexperiencedatleasta CNP due to MS. The results support previously published
30 %reductioninpainis,therefore,encouraging;however, proposalsthatanEERWstudydesignmaybeofparticular
the large placebo response somewhat confounds this find- value in identifying clinically relevant responses in this
ing. It is also reassuring that patients receiving THC/CBD patient population, and suggest that future studies may
sprayreportedananalgesiceffectinphaseBofthisstudy. benefit from the incorporation of a balanced dosing regi-
As well as the demonstrated placebo effect, the con- men between the different arms of the study.
ventional parallel-group, placebo-controlled, randomized Trial Information The ClinTrials.gov Trial Number for
studydesignusedinphaseAcouldalsohaveimpactedthe this study is NCT00391079.
findings from this study. This approach only provides
information about the average response to treatment, and Acknowledgments This study was sponsored and fully funded by
GW Pharma Ltd. Investigators received research grants from GW
includes results for subjects who do not respond to treat-
PharmaLtdtocoverthecostsofthestudyandhadaninputintothe
ment. In a population with a high proportion of nonre-
writingofthispaper.
sponders, such as may occur in chronic refractory
neuropathic pain, it may simply be the case that any gen- Conflicts of interest R. Langford, J. Mares, A. Novotna, M.
Vachora, I. Novakova, W. Notcutt, and S. Ratcliffe were all inves-
uine differences between drug and placebo are masked by
tigatorsinthisstudyandtheirorganizationsreceivedinvestigatorfees
the high rate of nonresponders. If this happens, the results
fromGWPharmaLtd.accordinglyfortheirparticipationinthestudy.
may not tell us much about the effectiveness of the medi- R.Langford,W.Notcutt,andS.Ratcliffehavereceivedconsultancy
cineinaclinicalsetting,wherepatientswhofailtorespond andspeakerfeesfromGWPharmaLtd.toattendmeetings.
would not usually continue treatment. In 2008, McQuay
Ethicalstandard Allhumanstudiesmuststatethattheyhavebeen
et al. [28] concluded that the enriched enrolment random-
approvedbytheappropriateethicscommitteeandhavethereforebeen
ized-withdrawal (EERW) design, rather than the conven- performedinaccordancewiththeethicalstandardslaiddowninthe
tional design, is potentially valuable in addressing this 1964DeclarationofHelsenki.
question, and should be considered especially in the study
of chronic pain to avoid the false conclusion of lack of
efficacy. Phase B of this study incorporated an EERW
design and the efficacy findings were statistically signifi- References
cant in favor of THC/CBD spray. The randomized-with-
drawal from THC/CBD spray precipitated a worsening in 1. Richards RG, Sampson FC, Beard SM, Tappenden P (2006) A
review of the natural history and epidemiology of multiple
the majority of the outcome measures, while maintenance
sclerosis: implications for resource allocation and health eco-
ofeffectofTHC/CBDspraywasdemonstrated.Theresults
nomicmodels.HealthTechnolAssess6(10):1–73
from phase B support the proposal that the efficacy of 2. FoxCM,BensaS,BrayI,ZajicekJP(2004)Theepidemiologyof
THC/CBD spray is maintained in long-term use. multiple sclerosis in Devon: a comparison of the new and old
classificationcriteria.JNeurolNeurosurgPsychiatry75:56–60
Intermsofsafety,itwasfoundthattheTHC/CBDspray
3. Merskey H, Bogduk N (1994) Classification of chronic pain.
wasgenerallywelltoleratedinthisstudy,withthemajority IASPPress,Seattle,pp1–222
of AEs considered to be mild to moderate in severity. 4. Clifford DB, Trotter JL (1984) Pain in multiple sclerosis. Arch
Three patients in the THC/CBD spray arm and two in the Neurol41:1270–1272
5. Vermote R, Ketelaer P, Carton H (1986) Pain in multiple scle-
placebo arm experienced a treatment-related SAE. The
rosispatients.ClinNeurolNeurosurg88:87–93
majority of AEs had resolved by the end of the study.
6. Moulin DE, Foley KM, Ebers GC (1988) Pain syndromes in
There was no evidence of a withdrawal syndrome in those multiplesclerosis.Neurology38:1830–1834
patientswhostoppedTHC/CBDspray,despiteaprolonged 7. StenagerE,KnudsenL,JensenK(1991)Acuteandchronicpain
syndromesinmultiplesclerosis.ActaNeurolScand84:197–200
period on the medicine.
8. Bonica JJ (1991) Introduction Semantic, Epidemiologic, and
In summary, we found that in this treatment-resistant
EducationalIssues.In:CaseyKL(ed)PainandCentralNervous
population, the THC/CBD spray showed a high response SystemDiseaseTheCentralPainSyndromes.RavenPress,Ltd.
rate, statistically different toplacebo at week 10 butnot at NewYork21
9. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup
the week 14 primary endpoint in phase A. Randomized-
NB, Jensen TS et al (2007) Pharmacologic management of
withdrawalfromTHC/CBDsprayprecipitatedasignificant
neuropathicpain:evidence-basedrecommendations.Pain132(3):
deterioration in pain scores in the placebo group, while 237–251
123
JNeurol(2013)260:984–997 997
10. SaartoT,WiffenP.Antidepressantsforneuropathicpain(2005) 21. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta-9-
TheCochraneDatabaseofSystematicReviews,Issue3.Art.No.: tetrahydrocannabinol/cannabidiolforneuropathicpainassociated
CD005454 with multiple sclerosis: an uncontrolled, open-label, 2-year
11. Wiffen PJ, McQuay HJ, Moore RA (2005) Carbamazepine for extensiontrial.ClinTher29(9):2068–2079
acute and chronic pain. The Cochrane Database of Systematic 22. IskedjianM,BrezzaB,GordonA,PiwkoC,EinarsonTR(2007)
Reviews,Issue3.Art.No.:CD005451 Meta-analysis of cannabis based treatments for neuropathic and
12. Zajicek P, Apostu VI (2011) Role of cannabinoids in multiple multiplesclerosis-relatedpain.CurrMedResOpin23(1):17–24
sclerosis.CNSDrugs25(8):187–201 23. BermanJS,SymondsC,BirchR(2004)Efficacy oftwocanna-
13. Cheng Y, Hitchcock SA (2007) Targeting cannabinoid agonists bis-basedmedicinalextractsforreliefofcentralneuropathicpain
for inflammatory and neuropathic pain. Expert Opin Investig frombrachialplexusavulsion:resultsofarandomisedcontrolled
Drugs16(7):951–965 trial.Pain299:306
14. Howlett AC,Barth F,BonnerTI,Cabral G,CasellasP,Devane 24. NurmikkoTJ,SerpellMG,HoggartB,ToomeyPJ,MorlionBJ,
WA et al (2002) International union of pharmacology. XXVII. Haines D (2007) Sativex successfully treats neuropathic pain
Classification of cannabinoid receptors. Pharmacol Rev 54(2): characterised byallodynia:arandomised double-blind,placebo-
161–202 controlledclinicaltrial.Pain133:210–220
15. Pertwee RG (2007) Cannabinoids and multiple sclerosis. Mol 25. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader
Neurobiol36:45–59 H, Knapp LE (2005) Relief of painful diabetic peripheral neu-
16. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermannson NO, ropathy with pregabalin: a randomized, placebo-controlled trial.
Leonova J et al (2007) The orphan receptor GPR55 is a novel JPain6(4):253–260
cannabinoidreceptor.BrJPharmacol152:984–986 26. SelvarajahD,GandhiR,WitteD,BowlerH,EmeryC,TesfayeS
17. Pertwee R (2001) Cannabinoid receptors and pain. Prog Neuro- (2006)TreatmentofpainfuldiabeticneuropathywithNabiximols
biol63:569–611 (a cannabis-based medicinal product)—results of a randomised
18. BeggM,DaleN,LlaudetE,MollemanA(2002)Modulationof placebocontrolledtrial.Diabetologia49(Suppl1):671–672
the release of endogenous adenosine by cannabinoids in the 27. TheCommitteeForMedicinalProductsForHumanUse(CHMP)
myenteric plexus-longitudinalmusclepreparationoftheguinea- Guideline On Clinical Investigation Of Medicinal Products
pigileum.BrJPharmacol137(8):1298–1304 Intended For The Treatment Of Neuropathic Pain, London, 18
19. MHRA Public Assessment Report. Nabiximols Oromucosal November2004CHMP/EWP/252/03
Spray (delta-9-tetrahydrocannabinol and cannabidiol)—PL 28. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V (2008)
18024/0009;UK/H/2462/001/DChttp://www.mhra.gov.uk/home/ Enriched enrolment with randomised withdrawal (EERW): time
groups/par/documents/websiteresources/con084961.pdf (2010, for a new look at clinical trial design in chronic pain. Pain
accessedNovember2011) 135(3):217–220
20. RogDJ,NurmikkoTJ,FriedeT,YoungCA(2005)Randomized
controlledtrialofcannabisbasedmedicineincentralpaindueto
multiplesclerosis.Neurology65:812–819
123
